Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16546679 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL6551956 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL30416085 | 0.81 | DRD2 (0.55) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL19954286 | 0.81 | DRD2 (0.55) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL3867807 | 0.79 | KDM4E (0.64) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL13711971 | 0.79 | KCNH2 (0.71) | ALDH1A1POLBKCNH2HTR1A | |
| SCHEMBL5677569 | 0.78 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL15800694 | 0.78 | PLD1 (0.73) | ALDH1A1KDM4EMAPTPOLBKCNH2 | |
| SCHEMBL21353591 | 0.78 | — | — | |
| SCHEMBL29857922 | 0.78 | PLD1 (0.73) | ALDH1A1KDM4EMAPTPOLBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NOS1, NOS2, NOS3 | ALDH1A1 507/4885KDM4E 4188/4885MAPT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.